Recent in vivo advances in cell-penetrating peptide-assisted drug delivery

被引:104
作者
Kurrikoff, Kaido [1 ]
Gestin, Maxime [2 ]
Langel, Ulo [1 ,2 ]
机构
[1] Univ Tartu, Inst Technol, Ulikooli 18, EE-50090 Tartu, Estonia
[2] Stockholm Univ, Dept Neurochem, S-10691 Stockholm, Sweden
基金
瑞典研究理事会;
关键词
CPP; in vivo delivery vectors; cell penetrating peptides; peptide vectors; Activatable CPP; drug delivery vectors; ENHANCED ANTICANCER ACTIVITY; CENTRAL-NERVOUS-SYSTEM; GENE DELIVERY; CANCER-THERAPY; FUSION PROTEIN; SIRNA DELIVERY; TUMOR-CELLS; MATRIX METALLOPROTEINASE-2; MODIFIED NANOPARTICLES; MULTIDRUG-RESISTANCE;
D O I
10.1517/17425247.2016.1125879
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Delivery of macromolecular drugs is an important field in medical research. However, macromolecules are usually unable to cross the cell membrane without the assistance of a delivery system. Cell penetrating peptides (CPPs) are unique tools to gain access to the cell interior and deliver a bioactive cargo into the cytosol or nucleus. In addition to macromolecular delivery, CPPs have been used to deliver smaller bioactive molecules. Therefore CPPs have become an intensive field of research for medical treatment. Areas covered: In this review, we highlight studies that include CPP in vivo disease models. We review different strategies and approaches that have been used, with specific attention on recent publications. The approaches that have been used include CPP-cargo covalent conjugation strategies and nanoparticle strategies. Various additional strategies have been used to achieve disease targeting, including active targeting, passive targeting, and combined active/passive strategies. As a result, delivery of various types of molecule has been achieved, including small drug molecules, proteins and nucleic acid-based macromolecules (e.g. siRNA, antisense nucleotides and plasmid DNA). Expert Opinion: Despite recent advances in the field, confusions surrounding CPP internalization mechanisms and intracellular trafficking are hindering the development of new and more efficient vectors. Nevertheless, the recent increase in the number of publications containing in vivo CPP utilization looks promising that the number of clinical trials would also increase in the near future.
引用
收藏
页码:373 / 387
页数:15
相关论文
共 83 条
[1]   Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides [J].
Aguilera, Todd A. ;
Olson, Emilia S. ;
Timmers, Margaret M. ;
Jiang, Tao ;
Tsien, Roger Y. .
INTEGRATIVE BIOLOGY, 2009, 1 (5-6) :371-381
[2]   Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo [J].
Andaloussi, Samir E. L. ;
Lehto, Taavi ;
Maeger, Imre ;
Rosenthal-Aizman, Katri ;
Oprea, Iulian I. ;
Simonson, Oscar E. ;
Sork, Helena ;
Ezzat, Kariem ;
Copolovici, Dana M. ;
Kurrikoff, Kaido ;
Viola, Joana R. ;
Zaghloul, Eman M. ;
Sillard, Rannar ;
Johansson, Henrik J. ;
Hassane, Fatouma Said ;
Guterstam, Peter ;
Suhorutsenko, Julia ;
Moreno, Pedro M. D. ;
Oskolkov, Nikita ;
Haelldin, Jonas ;
Tedebark, Ulf ;
Metspalu, Andres ;
Lebleu, Bernard ;
Lehtioe, Janne ;
Smith, C. I. Edvard ;
Langel, Uelo .
NUCLEIC ACIDS RESEARCH, 2011, 39 (09) :3972-3987
[3]   Influence of stearyl and trifluoromethylquinoline modifications of the cell penetrating peptide TP10 on its interaction with a lipid membrane [J].
Anko, Maja ;
Majhenc, Janja ;
Kogej, Ksenija ;
Sillard, Rannard ;
Langel, Ulo ;
Anderluh, Gregor ;
Zorko, Matjaz .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2012, 1818 (03) :915-924
[4]   Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models [J].
Apte, Anjali ;
Koren, Erez ;
Koshkaryev, Alexander ;
Torchilin, Vladimir P. .
CANCER BIOLOGY & THERAPY, 2014, 15 (01) :69-80
[5]   Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity [J].
Biswas, Swati ;
Dodwadkar, Namita S. ;
Deshpande, Pranali P. ;
Parab, Shruti ;
Torchilin, Vladimir P. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2013, 84 (03) :517-525
[6]   Octa-arginine-modified pegylated liposomal doxorubicin: An effective treatment strategy for non-small cell lung cancer [J].
Biswas, Swati ;
Deshpande, Pranali P. ;
Perche, Federico ;
Dodwadkar, Namita S. ;
Sane, Shailendra D. ;
Torchilin, Vladimir P. .
CANCER LETTERS, 2013, 335 (01) :191-200
[7]   Cellular uptake and spread of the cell-permeable peptide penetratin in adult rat brain [J].
Bolton, SJ ;
Jones, DNC ;
Darker, JG ;
Eggleston, DS ;
Hunter, AJ ;
Walsh, FS .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2000, 12 (08) :2847-2855
[8]   In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation [J].
Bucci, M ;
Gratton, JP ;
Rudic, RD ;
Acevedo, L ;
Roviezzo, F ;
Cirino, G ;
Sessa, WC .
NATURE MEDICINE, 2000, 6 (12) :1362-1367
[9]  
Cao GD, 2002, J NEUROSCI, V22, P5423
[10]   Activable Cell-Penetrating Peptide Conjugated Prodrug for Tumor Targeted Drug Delivery [J].
Cheng, Hong ;
Zhu, Jing-Yi ;
Xu, Xiao-Ding ;
Qiu, Wen-Xiu ;
Lei, Qi ;
Han, Kai ;
Cheng, Yin-Jia ;
Zhang, Xian-Zheng .
ACS APPLIED MATERIALS & INTERFACES, 2015, 7 (29) :16061-16069